TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as ...
Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today ...
BMO Capital Markets agreed to pay more than $40 million to settle U.S. Securities and Exchange Commission charges it failed ...
BOSTON, MA / ACCESSWIRE / January 13, 2025 / Block & Leviton is investigating TransMedics Group, Inc. (Nasdaq:TMDX) for potential securities ...
Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant ...
The ASX slumped further on Monday, with the S&P/ASX 200 index down 1.23% following strong US jobs data, dashing hopes of an ...
Investor's Business Daily on MSN2h
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...
Investor's Business Daily on MSN58m
J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer DrugJohnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies.
Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback